Figure 4.
RNF4 is recruited to WT and L217F-PML bodies, but not the A216T variant. (A) Anti-PML, RNF4, and ubiquitin immunoblots from purified PML bodies containing YFP-PML-V WT, A216T, and L217F. (B) Representative images assessing colocalization of RNF4 with YFP-PML-V WT, A216T, and L217F after 1 μM arsenic treatment for 2 h studied by fluorescence microscopy. Merge shows DAPI (blue), YFP (green), and RNF4 (red). (C) Quantitation summary of the colocalization data described in B. Columns are averages with SEM error bars. Colocalization was defined as any RNF4 signal above background within a PML body. Statistical significance was assessed by comparing the arsenic-treated conditions among the three PML types using Dunn’s multiple comparisons tests after Kruskal–Wallis ANOVA. The number of cells counted (n) is indicated in the chart. Source data are available for this figure: SourceData F4.

RNF4 is recruited to WT and L217F-PML bodies, but not the A216T variant. (A) Anti-PML, RNF4, and ubiquitin immunoblots from purified PML bodies containing YFP-PML-V WT, A216T, and L217F. (B) Representative images assessing colocalization of RNF4 with YFP-PML-V WT, A216T, and L217F after 1 μM arsenic treatment for 2 h studied by fluorescence microscopy. Merge shows DAPI (blue), YFP (green), and RNF4 (red). (C) Quantitation summary of the colocalization data described in B. Columns are averages with SEM error bars. Colocalization was defined as any RNF4 signal above background within a PML body. Statistical significance was assessed by comparing the arsenic-treated conditions among the three PML types using Dunn’s multiple comparisons tests after Kruskal–Wallis ANOVA. The number of cells counted (n) is indicated in the chart. Source data are available for this figure: SourceData F4.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal